NewsSTAT
Heuristic editor, no API keyVerdict: NotableSTAT+: Lilly's Jaypirca approved as first-line CLL therapy
Eli Lilly's Jaypirca has won FDA approval for previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma.
Score█████░░░░░4.7
VerdictWorth a reader's time today.
Summary from the source
Eli Lilly’s Jaypirca has won FDA approval for previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma.
The editor's rubric
| Dimension | Level | Weight | What that level means |
|---|---|---|---|
| Leverage | ██░░░ 2 | 15% | Reusable within one subfield (a technique, dataset, or protocol a few groups will adopt). |
| Magnitude | ███░░ 3 | 20% | Large gain: roughly 2x, or a clear new state of the art on a hard, unsaturated problem. |
| Evidence | ███░░ 3 | 20% | Solid: multiple benchmarks or cohorts, ablations, fair baselines, released code or data. |
| Novelty | ██░░░ 2 | 10% | A new combination of known ideas. |
| Trajectory | ██░░░ 2 | 10% | Some room to improve with obvious engineering. |
| Stakes | ███░░ 3 | 25% | Meaningful benefit to many people within a few years. |
Editor’s rationale
Heuristic triage from title and abstract text only, not a reading of the paper. Cues found: gains (won); verification (error bars); stakes (major disease, prevention or cure).
How the score was computed
Score█████░░░░░4.7
- Merit
- 5.3 / 10
- Adjusted merit
- 4.4 / 10
- Attention
- 28%
- Freshness
- 73%